Ratings GSK plc

Equities

GSK

GB00BN7SWP63

Market Closed - London S.E. 16:35:28 12/07/2024 BST 5-day change 1st Jan Change
1,517 GBX +0.80% Intraday chart for GSK plc +0.40% +4.61%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • With a P/E ratio at 11.34 for the current year and 9.6 for next year, earnings multiples are highly attractive compared with competitors.
  • The company has a low valuation given the cash flows generated by its activity.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
+4.61% 79.27B
B
+61.89% 841B
C+
+40.42% 625B
B
-4.31% 360B
C+
+17.52% 327B
B-
+9.68% 300B
C+
+15.66% 242B
B+
+17.90% 227B
B-
+14.99% 174B
C+
+0.76% 162B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes